TriSalus Life Sciences, Inc./$TLSI
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About TriSalus Life Sciences, Inc.
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.
- Ticker
- $TLSI
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 102
- Headquarters
- Westminster, United States
- Website
- trisaluslifesci.com
TLSI Metrics
BasicAdvanced
$200M
-
-$1.15
0.43
-
Price and volume
Market cap
$200M
Beta
0.43
52-week high
$7.95
52-week low
$2.20
Average daily volume
171K
Financial strength
Current ratio
5.348
Quick ratio
4.721
Long term debt to equity
5.219
Total debt to equity
5.256
Interest coverage (TTM)
-5.23%
Profitability
EBITDA (TTM)
-29.949
Gross margin (TTM)
85.79%
Net profit margin (TTM)
-62.59%
Operating margin (TTM)
-67.68%
Effective tax rate (TTM)
-0.05%
Revenue per employee (TTM)
$440,000
Management effectiveness
Return on assets (TTM)
-36.75%
Return on equity (TTM)
438.31%
Valuation
Price to revenue (TTM)
3.606
Price to book
30.5
Price to tangible book (TTM)
30.5
Price to free cash flow (TTM)
-6.981
Free cash flow yield (TTM)
-14.32%
Free cash flow per share (TTM)
-0.466
Growth
Revenue change (TTM)
25.25%
Earnings per share change (TTM)
-2.99%
3-year revenue growth (CAGR)
45.13%
3-year earnings per share growth (CAGR)
-29.20%
TLSI Financial Performance
Revenues and expenses
TLSI Earnings Performance
Company profitability
Upcoming events
No upcoming events
TLSI News
AllArticlesVideos
TriSalus Life Sciences to Host Third Quarter 2026 Financial Results Conference Call
Business Wire3 weeks ago
TriSalus Secures FDA Clearance For TriNav Advance as Stock Tests Key Support
Benzinga2 months ago
TriSalus Life Sciences Receives FDA Clearance for TriNav® Advance, Strengthening Comprehensive Pressure-Enabled Drug Delivery™ (PEDD™) Portfolio for Liver Embolization
Business Wire2 months ago
Funds containing TLSI
Fund name | Fund size | $TLSI weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.00% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.